Alkarnit – amino acids and their derivatives.

For urgent and long-term treatment of patients with congenital disturbance of metabolism that results in secondary deficit of a carnitine.

For prevention and treatment of deficit of a carnitine at the patients with an end-stage of a renal failure undergoing dialysis.

Structure

• active ingredient: left carnitine;
• 1 ml of solution the left carnitine in terms of 100% contains substance – 200 mg;
• other components: Acidum hydrochloricum or sodium hydroxide, water for injections.

Contraindication

Hypersensitivity to medicine components.

Side reactions

from digestive tract. Various moderate gastrointestinal disturbances were observed at long reception of an oral left carnitine, including rapid nausea and vomiting, an abdominal pain and diarrhea. Also at patients the specific smell of a body was shown. The dose decline often reduces or eliminates gastrointestinal symptoms and manifestations of a specific smell of a body.

from blood and lymphatic system. Increase at patients of MNV was seldom or never noted.

Neurologic reactions. Spasms were established at patients with the convulsive activity shown earlier or without it at introduction of a left carnitine both orally and intravenously. At patients with earlier existing convulsive activity the increase in frequency of attacks and/or their weights is registered.

Route of administration

ALKARNIT intravenously slowly within 2–3 minutes.

Metabolic disturbances

Recommended dosage makes 50 mg/kg in the form of a slow bolyusny injection within 2-3 minutes or infusion. Often patients with heavy metabolic crisis are given a dose of loading on which the equivalent dose within the next 24 hours is necessary. It is necessary to administer the medicament by infusion or an intravenous injection each 3 or 4 hours and by no means not less than in 6 hours. It is recommended that all subsequent daily doses were in the range of 50 mg/kg or depending on therapeutic need. The maximum allowed dosage makes 300 mg/kg. It is recommended by

to p that concentration of a carnitine in blood plasma is reached prior to this parenteral therapy. Weekly and monthly monitoring is also recommended. This monitoring has to include biochemical analysis of blood, indicators of the vital functions, indicators of concentration of a carnitine in plasma (concentration of a free carnitine in blood plasma has to make from 35 to 60 µmol/l) and the general clinical state.

Feature of use

Use during pregnancy or feeding by a breast

As researches of reproductive function on animals not always mean reaction of the person, use is possible only in case of emergency. However sufficient and well controlled researches on pregnant women are absent.

. A left carnitine – a usual component of breast milk.

Considering serious consequences of karnitinovy insufficiency for the pregnant woman, the risk of interruption of treatment is considered a left carnitine for mother big, than theoretical risk for a fruit in case of treatment continuation.

Children

to use Drug to children from the first day of life, including premature.

Ability to influence speed of response at control of motor transport or other mechanisms

.

Overdose

Is not present the confirmed data on toxicity of a left carnitine at overdose. High doses of medicament can cause diarrhea.

Treatment. To take measures for removal of medicament from a digestive tract in case of intake. To carry out symptomatic and maintenance therapy. Levokarnitin easily leaves from blood plasma by dialysis. Did not report about the cases threatening overdose life.

Simultaneous use of glucocorticoids leads

to accumulation of a left carnitine in body tissues (except a liver). Other anabolic means enhance effect of drug.

by

At the patients receiving anticoagulants of a coumarinic row along with a left carnitine observed very exceptional cases of increase in the international normalized relation (INR). MNV or other corresponding coagulative test should be carried out weekly until indicators become stable, and monthly after that at the patients accepting such anticoagulants together with a left carnitine.

Storage conditions

to Store

in original packing at a temperature not above 25 °C. To store out of children's reach.